Open AccessImportant Pharmacogenetic Information for Drugs Prescribed During the SARS‐CoV‐2 Infection (COVID‐19)
Author(s) -
Zubiaur Pablo,
Koller Dora,
SaizRodríguez Miriam,
NavaresGómez Marcos,
AbadSantos Francisco
Publication year - 2020
Publication title -
clinical and translational science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.303
H-Index - 44
eISSN - 1752-8062
pISSN - 1752-8054
DOI - 10.1111/cts.12866
Subject(s) - pharmacogenetics , covid-19 , medicine , pandemic , drug , intensive care medicine , coronavirus , medline , pharmacology , disease , virology , infectious disease (medical specialty) , biology , genotype , biochemistry , outbreak , gene
In December 2019, the severe acute respiratory syndrome virus‐2 pandemic began, causing the coronavirus disease 2019. A vast variety of drugs is being used off‐label as potential therapies. Many of the repurposed drugs have clinical pharmacogenetic guidelines available with therapeutic recommendations when prescribed as indicated on the drug label. The aim of this review is to provide a comprehensive summary of pharmacogenetic biomarkers available for these drugs, which may help to prescribe them more safely.